Posted by Michael Wonder on 31 May 2023
Brukinsa approved in Canada for the treatment of chronic lymphocytic leukaemia
30 May 2023 - BeiGene’s Bruton's tyrosine kinase inhibitor is approved in more than 65 markets globally.
BeiGene announced today that Brukinsa (zanubrutinib), a Bruton's tyrosine kinase inhibitor, has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukaemia.
